Gut and Liver

The Korean Association for the Study of the Liver (대한간학회)
권호 표지
DOI QR코드

DOI QR Code

The More, the Better? Predicting Prognosis in Primary Biliary Cholangitis

  • Kim, Bo Hyun (Center for Liver Cancer, National Cancer Center)
  • Published : 2018.11.15
⟨ Previous Next ⟩

Abstract

Keywords

References

  1. Kim KA, Ki M, Choi HY, Kim BH, Jang ES, Jeong SH. Populationbased epidemiology of primary biliary cirrhosis in South Korea. Aliment Pharmacol Ther 2016;43:154-162. https://doi.org/10.1111/apt.13448
  2. Zhang LN, Shi TY, Shi XH, et al. Early biochemical response to ursodeoxycholic acid and long-term prognosis of primary biliary cirrhosis: results of a 14-year cohort study. Hepatology 2013;58:264-272. https://doi.org/10.1002/hep.26322
  3. Pares A, Caballeria L, Rodes J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology 2006;130:715-720. https://doi.org/10.1053/j.gastro.2005.12.029
  4. Corpechot C, Abenavoli L, Rabahi N, et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology 2008;48:871-877. https://doi.org/10.1002/hep.22428
  5. Corpechot C, Chazouilleres O, Poupon R. Early primary biliary cirrhosis: biochemical response to treatment and prediction of longterm outcome. J Hepatol 2011;55:1361-1367. https://doi.org/10.1016/j.jhep.2011.02.031
  6. Kuiper EM, Hansen BE, de Vries RA, et al. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology 2009;136:1281-1287. https://doi.org/10.1053/j.gastro.2009.01.003
  7. Lammers WJ, Hirschfield GM, Corpechot C, et al. Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy. Gastroenterology 2015;149:1804-1812.e4. https://doi.org/10.1053/j.gastro.2015.07.061
  8. Carbone M, Sharp SJ, Flack S, et al. The UK-PBC risk scores: derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis. Hepatology 2016;63:930-950. https://doi.org/10.1002/hep.28017
  9. Yoo JJ, Cho EJ, Lee B, et al. Prognostic value of biochemical response models for primary biliary cholangitis and the additional role of the neutrophil-to-lymphocyte ratio. Gut Liver 2018;12:714-721. https://doi.org/10.5009/gnl18271
  10. Yang F, Yang Y, Wang Q, et al. The risk predictive values of UKPBC and GLOBE scoring system in Chinese patients with primary biliary cholangitis: the additional effect of anti-gp210. Aliment Pharmacol Ther 2017;45:733-743. https://doi.org/10.1111/apt.13927
  11. Imtiaz F, Shafique K, Mirza SS, Ayoob Z, Vart P, Rao S. Neutrophil lymphocyte ratio as a measure of systemic inflammation in prevalent chronic diseases in Asian population. Int Arch Med 2012;5:2. https://doi.org/10.1186/1755-7682-5-2
  12. Martin HL, Ohara K, Kiberu A, Van Hagen T, Davidson A, Khattak MA. Prognostic value of systemic inflammation-based markers in advanced pancreatic cancer. Intern Med J 2014;44:676-682. https://doi.org/10.1111/imj.12453